Association Between Immune-Related Adverse Events During Anti-PD-1 Therapy and Tumor Mutational Burden.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 31436791.
- Also identified by DOI 10.1001/jamaoncol.2019.3221 and PMC identifier 6707013.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This database study compares surveillance data on immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitors to determine whether irAEs experienced during anti–PD-1 therapy correlate with tumor mutational burden across 18 cancer types.